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1 Introduction 
Though the increasing use of ventricular assist devices has contributed to a declining 
mortality of patients with end-stage heart failure in recent years, the concomitant life-
threatening complications such as thromboembolism and infection limit the 
widespread clinical application of this category of mechanical devices in sustaining 
lives of patients with terminal heart failure. So far, heart allotransplantation (alloTx) 
has remained the definitive therapy for end-stage heart failure despite its limitations 
for the patient, such as a long waiting time and long period of hospitalization before a 
suitable human donor is available. However, despite concerted, persistent societal 
efforts to increase the availability of organs from cadaveric donors, we are still faced 
with increasing discrepancy between the availability of donated human organs and 
the demand for transplantation. Therefore, the need for a new source of organs 
including hearts for clinical transplantation has been increasing for decades and 
xenotransplantation is widely considered to open a new pathway to resolve this 
issue. 
1.1 History of xenotransplantation 
Xenotransplantation refers to any procedure that involves the transplantation, 
implantation, or infusion into a human recipient of either living cells, tissues, or 
organs from a non-human animal source or human body fluids, cells, tissues, or 
organs that have had ex vivo contact with living non-human animal cells, tissues or 
organs. 
  The history of xenotransplantation dates back to 1682 when a Russian 
physician reportedly repaired the skull of a wounded nobleman using a piece of bone 
from a dog [1]. Blood transfusions from various animals to humans were attempted 
as early as the seventeenth century despite being associated with major 
complications and even death [2]. It was not until early in the twentieth century that 
scientists began to attempt to transplant tissues across the species barrier. In 1905, 
a French surgeon transplanted slices of rabbit kidney into a child with renal failure [1] 
followed by other doctors who attempted transplantation of organs from the pig, goat, 
lamb and non-human primate into patients. It is no surprise that all of the attempts 
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failed due to a lack of the fundamental knowledge of the immunological mechanism 
of organ rejection. Consequently, scientific interest in the transplantation of tissues or 
organs from animal to human waned.  
In the 1960s a revival of xenotransplantation was witnessed in the world, 
pioneered by Keith Reemtsma who transplanted chimpanzee or baboon kidneys into 
thirteen patients with terminal renal failure when human organs were not available. 
One recipient survived for nine months but the others died within days. In 1964, 
James Hardy attempted the transplantation of a chimpanzee heart and other cardiac 
attempts of such kind followed [3]. All of these attempts were ultimately unsuccessful 
with unacceptable rates of organ failure and early mortality. Thereafter, this revival 
eventually died as well.  
Recent advances in the understanding of organ rejection and development of 
new immunosuppressive drugs again rekindled interest in xenotransplantation. The 
best known clinical cardiac xenotransplantation was that performed by Leonard 
Bailey, who transplanted a baboon heart into an infant girl, known as Baby Fae, in 
1983. The surgical procedure in Baby Fae was technically successful, but the graft 
underwent acute rejection and the patient died 20 days later [3]. 
1.2 Immunological barriers to xenotransplantation 
1.2.1 Hyperacute rejection 
Pigs are thought to be the best source animal species for clinical 
xenotransplantation. The selection of pigs as the preferable donor species is based 
on its ready availability, the physiologic and organ size compatibility, and the fact that 
use of non-human primate species would pose unexpected ethical, infectious, and 
logistical issues [4-6]. Moreover, in 1999, there was a moratorium on the use of non-
human primates as organ donors imposed by FDA (Food and Drug Administration of 
United States) citing the risk of cross-species infection. 
Transplantation of an unmodified pig heart into a non-immunosuppressed 
human or non-human primate results inevitably in destruction of the graft within 
minutes or hours, which is known as a process termed hyperacute rejection (HAR). 
In the event of HAR, the binding of pig antigens to human or primate natural 
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(preformed) antibodies initiates activation of the complement and coagulation 
systems, leading to a constellation of events characterized by intravascular 
thrombosis, endothelial injury, interstitial hemorrhage and edema, and cellular 
infiltration in the tissue [7–9]. 
The main target for human preformed antibodies is galactose-α-1,3-galactose 
(α-Gal) [10,11], an oligosaccharide that is not present in human beings, apes, and 
Old World monkeys [12]. This carbohydrate epitope is synthesized by the enzyme, α-
1,3-galactosltransferase, which glycosylates N-acetyllactosamine of various 
glycoproteins on the surface of many porcine cells, among which are vascular 
endothelial cells [13–15]. 
HAR is primarily mediated by preformed xenogeneic natural antibody (XNA) 
against the α-Gal epitope, most of which is immunoglobulin M (IgM). It is reported 
that more than 80% of the total amount of XNAs in human serum is directed against 
the α-Gal epitope and around 1% of peripheral B cells synthesize anti- α-Gal 
antibodies [16–18]. Among XNAs against α-Gal epitope IgM is thought to initiate 
HAR other than other immunoglobulin isotypes such as immunoglobulin G (IgG) and 
immunoglobulin A (IgA) [19–20]. Hyperacute rejection may not occur in 
xenotransplantation between closely-related species, a so called concordant 
transplantation (e.g. transplantation from non-human primate to human). As opposed 
to concordant transplantation, discordant transplantation represents another 
category of xenotransplantation accomplished between two distantly-related species 
(e.g. transplantation from pig to human, transplantation from pig to rat). Concordant 
species usually have a closer phylogenic relationship than discordant animals. In 
discordant TX, the recipient normally harbours preformed antibodies against surface 
antigens on the cells of the donor organ, which initiate vigorous HAR shortly after 
xenotransplantation. Nonetheless, some therapeutic strategies prove to be effective 
in preventing HAR such as removing natural antibody or neutralizing complement. 
1.2.2 Acute humoral xenograft rejection 
A delayed antibody-mediated rejection after xenotransplantation is called “acute 
humoral xenograft rejection” (AHXR , also termed delayed xenograft rejection (DXR) 
or acute vascular rejection (AVR)) [21]. In this case, elicited (IgM and IgG) antibodies 
recognize and bind to Gal and other non-Gal antigens on the vascular endothelium. 
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This leads to complement and subsequent vascular endothelial cell activation, 
followed by injuries caused by the complement and cellular components of the innate 
immune system. 
Natural killer (NK) cells play a role in AHXR [22–24] as well as macrophages 
[25], but their exact implication remains unclear. AHXR may occur despite the 
administration of conventional immunosuppressive agents, and is particularly 
observed following a T-cell-dependent elicited antibody response. 
1.2.3 Acute cellular rejection 
Cellular immunity plays a significant role in the development of xenograft failure [26–
30]. However, few studies of acute cellular rejection (ACR) in discordant 
xenotransplantation have been reported, possibly because T-cell activation normally 
results in a rapid elicited antibody response that leads to AHXR before significant T-
cell infiltration develops in the xenograft. T-cell response contributes to the 
development of both ACR and AHXR through both direct and indirect pathways, but 
elicited antibody response often masks T-cell response and obscures the 
pathological findings of ACR in xenotransplantation. As a consequence, the role of T-
cell immunity in xenotransplantation is often underestimated. 
Even though the T-cell response is thought to be more vigorous in the 
xenograft than in the allograft [31–35], potent immunosuppressants can largely 
suppress ACR as well as T-cell-dependent AHXR. Therefore, acute cellular rejection 
is not typically seen under intense immunosuppressive protocol either [36–41]. 
1.2.4 Chronic rejection 
Chronic rejection is a major cause of graft loss in allotransplantation and is also 
considered to occur in xenotransplantation setting. However, very little information is 
available in the context of pig-to-primate xenotransplant, possibly due to the fact that 
long-term survival of xenografts is not routinely achieved owing to the preceding 
occurrence of AHXR. The development of chronic vasculopathy, which is considered 
to be a characteristic of chronic cardiac xenograft rejection, is associated with both 
humoral and cellular rejection. It is characterized by intimal thickening, fibrin 
exudation, complement and immunoglobulin deposition and cellular infiltration, 
similar to those seen in long-surviving allografts [42].  
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The causative factors of chronic rejection remain poorly understood. It is assumed 
that both chronic immune and non-immune elements are involved in this process 
and that the former is associated with both cellular and humoral immunity. 
1.2.5 Coagulation dysregulation 
It is known that there are definite molecular incompatibilities between the coagulation 
systems of pig and human, which may contribute to coagulation dysregulation, 
leading to thrombotic microangiopathy and eventual failure of pig xenograft. 
In a molecular analysis it is shown that pig thrombomodulin (TBM) is a poor 
cofactor for activation of human protein C in spite of its ability to bind human 
thrombin [31]. Pig TBM is estimated to possess only 1–10% of the capacity of human 
TBM in terms of generating activated protein C (APC) in the context of 
xenotransplantation [43–46]. 
The second pig–human molecular incompatibility has also been found to lie 
between von Willebrand factor (vWF) and platelet glycoprotein Ib (GPIb). Human 
platelets aggregate upon contact with pig vWF due to an aberrant interaction 
between the O-glycosylated A1 domain and human platelet GPIb, even in the 
absence of shear stress [47]. 
The third one is associated with tissue factor pathway inhibitor expressed by 
porcine endothelial cells, which does not effectively neutralize human factor Xa 
(FXa) [48, 49]. 
1.3 Strategies to overcome rejection in xenotransplantation 
Xenograft rejection is mediated by mechanisms that differ from those involved in 
alloreactivity and which are inadequately controlled solely by conventional 
immunosuppressive agents. Therefore, in addition to the use of immunosuppressive 
pharmaceutical therapy, the development of specific strategies is also required to 
overcome rejection episodes in the setting of xenotransplantation. This includes 
modification of the host immunity or production of genetically engineered organs, 
such as utilization of complement inhibitors, depletion of natural antibodies, and 
deletion of specific xenoantigens or introduction of protective transgenes by genetic 
modification of donor animals.  
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1.3.1 Immunosuppressive pharmaceutical therapy  
Immunosuppression can be achieved by depleting lymphocytes, diverting 
lymphocyte traffic, or blocking lymphocyte response pathways by a variety of 
immunosuppressive drugs, which include small-molecule drugs, depleting and non-
depleting protein drugs, intravenous immunoglobulin and glucocorticoids. Small-
molecule immunosuppressive agents include calcineurin-inhibitors (e.g. tacrolimus), 
target-of-rapamycin Inhibitors (e.g. sirolimus), inhibitors of nucleotide synthesis (e.g. 
mycophenolate mofetil), alkylating agent (e.g. cyclophosphamide) and azathioprine. 
Protein immunosuppressive drugs consist of polyclonal and monoclonal antibodies 
represented by polyclonal antithymocyte globulin, anti-CD3 monoclonal antibodies, 
anti-CD20 antibodies,anti–interleukin (IL)-2 receptor (anti-CD25) antibodies, anti-
CD52 antibodies, anti–tumour necrosis factor (TNF) reagents and LFA-1 
(lymphocyte function-associated antigen-1) inhibitors. The antibodies deplete 
circulating lymphocytes by direct cytotoxicity (both complement and cell-mediated) 
and block lymphocyte function by binding to cell surface molecules involved in the 
regulation of cell function.  
1.3.2 Complement inhibitors 
One effective approach to prevent hyperacute rejection is to administer complement 
inhibitory molecules. For instance, soluble complement receptor 1 [50] or cobra 
venom factor [50, 51] both inhibiting complement activity, have been used to obtain 
prolonged survival of the xenografts in xenogeneic transplantation models. Because 
of effective blockade of activation pathways, these factors are more efficient than 
complement 1 (C1) inhibitor [51]. As expected, their efficacies are inferior to those 
obtained in allotransplant. 
1.3.3 Depletion of natural antibodies 
Plasmapheresis represents one of the most common approaches to deplete XNAs in 
the periphery of the recipient. Plasmapheresis involves the replacement of recipient 
plasma by substitutes such as albumin. Thus, in addition to XNA, non-
immunoglobulin plasma proteins such as complement and coagulation factors are 
also depleted by this approach. To avoid these drawbacks, an antibody-based 
immunoadsorption (immunoapheresis) has been proposed, which allows depletion of 
total plasma IgG, IgA and IgM through immunoaffinity columns [52]. 
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Immunoadsorption offered some advantages in pig-to-baboon combination by 
lowering the anti-pig IgG, IgA and IgM antibody titters dramatically [53]. However, 
both plasmapheresis and immunopheresis methods are hampered by the removal of 
immunoglobulin non-specific for xenoantigens that leads to an increase in recipient 
vulnerability to opportunistic infections in the post-transplant period.  
1.3.4 Genetically engineered pigs 
As mentioned above, α-Gal epitope is the major target for human and non-human 
primate anti-pig antibodies and its binding to preformed XNAs mediates the 
hyperacute rejection. To disable the expression of α-Gal epitope on the surface of pig 
cells, deletion of α1,3-galactosyltransferase using a genetic engineering method was 
proposed. With the introduction of techniques of nuclear transfer and embryo 
transfer [54,55], knock-out of the gene for α1,3-galactosyltransferase in pigs was 
achieved, which proved to be one of the most significant advances that have been 
made in this field. Genetically modified αGalT-knockout (GTKO) pigs were first 
available for experimental studies in 2003 [56]. The first transplantation of organs 
from GTKO pigs into non-human primates was reported in 2005 [57–59], in which 
the incidence of hyperacute rejection of pig grafts was greatly reduced. 
Although the availability of GTKO pigs has been a major step forward, there are 
well documented natural antibodies to non-Gal antigens in humans and non-human 
primates [60–62], which are associated with hyperacute rejection or AHXR [40, 63], 
but the nature of which remains uncertain. Recent study suggested the elicited non-
Gal antibody response is directed to a limited number of non-Gal antigens, which 
comprise members of the heat shock and annexin protein families, porcine 
complement, and thromboregulatory proteins [64]. It is believed that substitution of 
the genes for these non-Gal targets could abrogate the elicited antibody response 
and maintain endothelial cell function so as to prolong graft survival. 
The presence of a complement-regulatory protein on the surface of vascular 
endothelial cells in the pig largely protects the graft from hyperacute rejection. 
Expression of a human complement-regulatory protein (hCRP) by genetically 
modified pigs might be effective in protecting the pig cells from lysis by activated 
complement system. Actually, incidence of hyperacute rejection was brought down 
when organs from pigs expressing one or more human complement-regulatory 
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proteins, such as CD46, CD55, or CD59 were transplanted into non-human primates 
[65–69]. It was further reduced in transplanted organs from GTKO pigs that also 
express hCRPs (GTKO/hCRP pigs) [70]. 
1.4 Orthotopic and heterotopic cardiac xenotransplantation 
The abdominal heterotopic cardiac xenotransplantation (CXTx) is an established 
model in the study of pig-to-non-human primate cardiac xenotransplantation, in 
which xenograft is perfused and beating but does not contribute to circulation. 
Specifically, the left ventricular cavity is not or only partially perfused via an atrial 
septum defect while coronary sinus blood is drained into the right ventricle. Thus, the 
heterotopic abdominal cardiac xenotransplantation is a non-working model especially 
with regard to the left ventricle. So far a median heterotopic cardiac xenograft 
survival of 3 months has been achieved [71], with individual survival in excess of 8 
months [72]. If these results can be replicated with life-supporting orthotopic 
transplantation the clinical application might be justified in the future. However, due 
to inherent problems of this orthotopic model predominantly in the early peri- and 
postoperative period a survival of more than 3 months has not been achieved (the 
survival ranges from 1 to 57 days [64]). This is one requirement of the ISHLT (The 
International Society for Heart and Lung Transplantation) Xenotransplantation 
Advisory Committee guidelines for initiation of a clinical trial [73]. 
In our pig-to-primate cardiac xenotransplantation project we demonstrated the 
feasibility of a heterotopic thoracic cardiac xenotransplantation technique (HTCXTx), 
which represents a life supporting model in which both the donor and recipient heart 
contribute to circulation. Good porcine cardiac graft function was maintained for up to 
50 days using clinically applicable immunosuppression [74]. Thereby, HTCXTx is a 
possible alternative to the orthotopic and abdominal heterotopic xenotransplantation 
models, which combines the advantages of both models.  
1.5 Application of telemetry system in cardiac xenotransplantation 
Evaluation of cardiac xenograft function in a pig-to-baboon xenotransplant model is 
difficult and time consuming, which has been traditionally accomplished by means of 
palpation, ultrasound and biopsy. However, those methods require frequent 
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application of anesthesia to the baboon, increasing the risk of complications such as 
bleeding, infection, and graft injury, leading to increased morbidity and possibly 
mortality rate and compromising the experiment sometimes.  
In recent years, telemetry has been widely applied in the life science research 
involving a wide variety of animal models, optimizing experiment conditions and 
facilitating data collection. The telemetry system enables the monitoring of animals 
while they move freely within their cages. Technically, a miniature transmitter 
implanted in each animal is capable of measuring one or more parameters (e.g. 
blood pressure, temperature, heart rate, ECG) with the data transmitted to a nearby 
receiver via radio frequency signals. The data may be collected and processed 
readily using the corresponding data acquisition system. 
The monitoring of heterotopic transplantation by telemetry has been described 
[75–78]. This system provides reliable measurement of graft function and advanced 
clues in case of infection, rejection, or loss of graft function. Importantly, this system 
also obviates repeated anesthesia of recipient baboons to evaluate the heart 
function required by traditional means, rendering measurements free from the effects 
of anesthesia. The ability to evaluate several parameters retrospectively is an added 
advantage of this system. 
Furthermore, this implantable system prevented manipulation by the primate 
recipients, which usually do not tolerate external leads and monitoring devices well 
unless the animals are heavily sedated or restrained. The technique provides more 
humane treatment of the recipients compared with traditional means [75]. 
In this study, we sought to assess the use of continuous telemetry as a non-
invasive method to monitor cardiac xenograft function in pig-to-non-human primate 
heterotopic thoracic cardiac xenotransplantation. By comparing the changes of 
telemetric signals with biochemical, immunological evidence obtained during the 
posttransplant period, we aimed to validate the role of this technique in detecting the 
onset of myocardial damage or acute immune response. 
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2 Materials and Methods 
2.1 Animals 
Care of animals was taken in accordance with the Guide for the Care and Use of 
Laboratory Animals based on the German Law for the Care of Experimental Animals 
(German Legislation for the Welfare of Laboratory Animals, article 5, §7 - §9a, 
Project -70-11). 
2.1.1 Donor animals – Pigs 
In this study, one double- (α-Gal KO + hCD46) and six triple-transgenic (α-Gal KO + 
hCD46 + hTM) pigs (fig.2.1) were used as organ donors. The Institute of Molecular 
Animal Breeding and Biotechnology, Gene Centre, Ludwig Maximilian University, 
Munich, Germany and Revivicor Inc., Blacksburg, VA, USA were jointly responsible 
for breeding them. 
 
Figure 2.1: Transgenic pigs before xenotransplantation. 
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After birth, the animals were examined by auscultation and echocardiography 
to ensure they are healthy as donors. The transgenesis was validated by ear biopsy 
and immunohistochemistry. At an age of 6-8 weeks, the animals, approximately 
weighing10-15 kg, were used for the experiment. With this age and body weight, the 
heart size of the donor pig matches the recipient baboon best. 
2.1.2 Recipient animals – Baboons 
The baboons (fig.2.2) were provided by the German Primate Center in Göttingen. 
Prior to delivery of the baboons, a broad variety of microbiological screening tests 
(e.g. Simian immunodeficiency virus, Simian T-Cell leukemia virus, Herpes papionis 
virus-2, Tuberculosis, Rabies) were performed. 
  
Figure 2.2: Baboon housed in a cage preoperatively. 
About six weeks before the transplant, the animals were taken to the Walter-
Brendel-Centre, which was used as a host laboratory for future reference. 
Postoperatively, each of them was kept in a large mobile cage specially designed to 
facilitate therapeutic treatment during the postoperative period. Once their physical 
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condition was stable, they were brought back into the normal cages. The general 
information of the recipients and donors is present in table 2.1. 
 
            Baboon Recipient            Pig Donors  
No. Sex Type BG  Age Weight Weight Transgenes 
1 
2 
3 
4 
5 
6 
7 
Male 
Male 
Male 
Male 
Male 
Male 
Male 
P.anubis 
P.anubis 
P.anubis 
P.anubis 
P.anubis 
P.anubis 
P.anubis 
AB 
B 
AB 
B 
B 
B 
B 
 5 years 
 6 years 
 6 years 
10 years 
10 years 
 7 years 
 8 years 
18kg 
24kg 
27kg 
28kg 
27kg 
23kg 
34kg 
14kg 
16 kg 
13 kg 
16 kg 
17 kg 
22 kg 
17 kg 
GalT-KO/hCD46 
GalT-KO/hCD46/hTM 
GalT-KO/hCD46/hTM   
GalT-KO/hCD46/hTM 
GalT-KO/hCD46/hTM  
GalT-KO/hCD46/hTM  
GalT-KO/hCD46/hTM    
Table 2.1: General information of recipient baboons and donor pigs. 
2.2 Preoperative treatment 
Central venous catheters were placed two days prior to transplantation (Arrow®, 14 
G, Arrow International Inc, USA). Jackets and tethering systems (LomirTM, Lomir 
Biomedical Inc, Canada) were used to protect the infusion system from damage by 
the baboons. 
Then, immunoadsorption was performed through the newly implanted catheters 
and repeated on the day of operation. 
2.3 Technique of heterotopic thoracic xenogeneic heart transplantation 
2.3.1 Explantation of donor heart 
Anesthesia was initiated by intramuscular injection of 10-20 mg / kg ketamine 
hydrochloride (Ketavet®, Pharmacia GmbH, Berlin, Germany), 10 mg / kg azaperone 
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(Stresnil®, Janssen Animal Health, Neuss, Germany) and 0.025 mg / kg atropine 
sulphate (Atropine sulfate Braun®, B. Braun Melsungen AG, Melsungen, Germany). 
After endotracheal intubation, the animals were mechanically ventilated with oxygen-
air mixture of 100% (Siemens Servo Ventilator 900C, Siemens-Elema system, AB, 
Solna, Sweden). Anesthesia was maintained using 7 mg / kg / h propofol (propofol 
2%, Fresenius Kabi GmbH, Bad Homburg, Germany) and 0.05 mg / kg / h fentanyl 
dihydrogencitrate (Fentanyl-Janssen®, Janssen Pharmaceuticals Inc, USA). 
After median sternotomy and systemic heparinization (500 IU / kg heparin 
(Heparin-Natrium-25000-ratiopharm®, ratiopharm GmbH, Ulm, Germany)), 
cardioplegic solution (50 ml / kg HTK Bretschneider solution (Custodiol®, Dr. Franz 
Köhler Chemie GmbH, Alsbach-Hähnlein, Germany)) was used to induce cardiac 
arrest. Before explantation of the heart, both venae cavae were ligated and then the 
ascending aorta and pulmonary trunk were separated as well as the pulmonary 
veins. Afterwards, the heart was harvested and stored in a sterile bag soaked in ice 
water before being weighed. 
2.3.2 Heterotopic thoracic cardiac transplantation 
2.3.2.1 Anesthesia 
Anesthesia was initiated by an intravenous dose of 3 mg / kg ketamine hydrochloride 
and 0.15 mg / kg midazolam (Midazolam-ratiopharm®, Ratiopharm GmbH, Ulm, 
Germany) and maintained by intravenous administration of 0.05 mg / kg / h fentanyl 
dihydrogencitrate and 5 to 10 mg / kg / h propofol. Thereafter, the baboon was 
endotracheally intubated (5.0 to 6.5 Hi-Lo LanzTM, Mallinckrodt, Athlone, Ireland) and 
mechanically ventilated with oxygen-air mixture of 40%. 
2.3.2.2 Surgical Technique 
After median sternotomy, the heart was exposed and then the aorta, vena cava 
superior and inferior were canullated. Subsequently, cardiopulmonary bypass (Hilite 
2800, Medos, Stolberg, Germany) was established following administration of 500 IU 
/ kg heparin. 
Anastomosis was performed between the left atria of both hearts and then the 
right atria. By means of an end-to-side anastomosis, the ascending aorta of the 
donor’s heart was linked to the recipient’s aorta. An end-to-side and side-to-side 
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anastomosis was also established to connect the two pulmonary trunks with a 
vascular prosthesis (Terumo Vascutek Gelweave, Ø 10 mm, Hamburg, Germany) 
(Fig. 2.3a, 2.3b, 2.3c) interposed. 
During reperfusion of the hearts, the telemetry monitoring system (DSI 
Monitoring, Data Science International Inc, St. Paul, MN, USA) was also implanted 
(please refer to 2.7 Telemetry system for details of the surgical technique). 
 
Figure 2.3a: Thoracic heterotopic cardiac transplantation (On the right is the native 
heart and the cardiac xenograft is on the left).  
    
Pulmonary artery 
Cardiac xenograft 
Native heart 
Cardiac xenograft 
Cardiac Xenograft 
Native heart 
 Figure 2.3c Figure 2.3b 
Figure 2.3a 
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Figure 2.3b: Thoracic heterotopic cardiac transplantation (Operative findings during 
anastomosis of the pulmonary arteries). Figure 2.3c: Thoracic heterotopic heart 
transplantation (Illustration of the position of the xenograft in the thorax of the 
recipient). 
2.4 Immunosuppressive therapy 
2.4.1 Immunosuppressant application 
To achieve a reduction of B-cells, T-cells and plasma cells and prevent secondary 
antibody production, we used a quadruple combination of rituximab, bortezomib, 
dexamethasone and cyclophosphamide, which had been effective in the treatment of 
multiple myeloma and was already used in clinic. The treatment was initiated about 
four weeks before operation. 
The immunosuppressive regimen is outlined in table 2.2. 
Drugs Dose Timing 
Anti CD20  19 mg/kg 
Preoperative days -28, -21, -14, -7, 0, 
+7 and +14 
Bortezomib  1,3 mg/m2 Preoperative days -28, -25,-21 and -18 
Dexamethasone  2 mg/kg 
3 cycles of 4 days following preoperative 
days -28, -20 and -13 
Antithymocyte  
globulin (ATG)  
Tacrolimus 
1.5 mg/kg/d iv infusion 
 
0.01 mg/kg/d iv infusion 
Preoperative days -2, -1 ,0 and 
postoperative days +1, +2 
Postoperative days 
MMF  20 mg/kg/ hr iv infusion Twice per day postoperatively 
Methylprednisolone 10 mg/kg iv injection 
Twice per day postoperatively, tapered 
off in 7 weeks 
Table 2.2: Pharmaceutical regimen applied perioperatively. 
2.4.2 Immunoadsorption 
This treatment was performed on the preoperative second day as well as the day of 
operation. 
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Immunoadsorption (TheraSorb Life18, MACS, Bergisch Gladbach) was utilized to 
reduce antibodies and immune complexes in the blood of the baboon recipients to 
around 20%. 
2.5 Non-immunosuppressive medication 
2.5.1 Acetylsalicylic acid 
To improve the coagulation system of recipient animals and thus to reduce the risk of 
pathological events such as embolism and infarct, baboons were given 50 - 75 mg 
acetylsalicylic acid intravenously a day from the 4th or 5th postoperative day onward 
(Aspirin®, Bayer Schering Pharma, Germany). 
2.5.2 Heparin 
Heparin was intravenously given to animals continuously by infusion pump to reduce 
the risk of thrombotic events post cardiac transplantation. The dose of heparin was 
adjusted to achieve aPTT (activated partial thromboplastin time) level of 35 to 45s. 
2.5.3 Gastrointestinal symptomatic medications 
To prevent gastrointestinal side effects caused by medication, the animals were 
given proton pump inhibitors (e.g. pantoprazol), H2 blockers (e.g. ranitidine) or 5 -HT3 
blockers (e.g. ondansetron). 
2.5.4 Antibiotics 
A variety of broad-spectrum antibiotics (e.g. Tazobac, Cefuroxim, Meropenem, 
Ciprofloxacin) were applied to prevent or treat the postoperative infection. The 
selection and dosage of antibiotics were based on body weight and antibiotic 
sensitivity test. 
2.5.5 Electrolyte supplementation 
According to the results of the regular assay of serum electrolyte post operation, 
electrolytes such as Ca2+, K+, Mg2+ were selectively given to animals by syringe 
pump continuously. 
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2.5.6 Analgesia 
Ketamine hydrochloride and metamizole sodium (Novaminsulfon-ratiopharm®, 
ratiopharm GmbH, Ulm, Germany) were administered for up to 10 days 
postoperatively. Dosages were adjusted to the condition of the animal. 
2.6 Laboratory tests 
Among a variety of laboratory tests which were not all involved in this study, troponin 
and anti-pig antibodies (APA) serum levels were determined on a daily basis. 
Troponin is analysed by the Institute of clinical chemistry of the University Hospital 
Grosshadern, University of Munich. 
Anti-pig hemolytic assay was performed according to an established protocol 
detailed in the appendix. 
2.7 Telemetry system 
2.7.1 Setup  
The telemetry equipment from Data Sciences International (DSI Inc, St. Paul, MN, 
USA), includes an implantable transmitter (Model TL11M3-D70-PCTP) (fig.2.4), a 
receiver (Model RMC1) (fig.2.5), a data processing device (Data Exchange Matrix) 
and an ambient pressure reference monitor (APR-1). The transmitter has two 
pressure catheters and two biopotential leads. The pressure catheter is a 14-cm fluid 
filled catheter with a terminal sensing region containing non-compressible fluid and a 
plug of biocompatible gel. This sensing region relays pressure waves to the DSI 
transmitter, which transmits both the pressure and biopotential signals to the receiver 
via radio frequency. The data processing system, which has a sampling frequency of 
500 Hz, is programmed to acquire and process these signals into data that is 
subsequently relayed to the system computer in a real time manner. As a result, real 
time pressure waves are displayed on the computer monitor as well as ECG 
obtained in a similar way. Ambient pressure reference monitor ensures accurate 
pressure measurements in animals when using DSI transmitters, by providing 
dynamic corrections to the digital signals acquired by the system. 
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Figure 2.4: The transmitter of a telemetry system. 
 
   
Figure 2.5: Receiver of the telemetry system in use. 
2.7.2 Surgical implantation of telemetry system 
One pressure catheter was inserted into the xenograft's left ventricle (fig.2.6) through 
the apex and secured using a 6-0 purse-string suture with pledgets. The other 
pressure catheter was implanted into the aorta. The two biopotential leads were 
sutured and fixed onto the ventricular epicardium for ECG monitoring. 
DSI receiver 
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The telemetry transmitter was placed in a subcutaneous pocket in the chest 
wall before the thoracic cavity was closed. Finally, the transmitter was externally 
activated by a magnet. 
    
Figure 2.6: Implantation of the ventricular pressure catheter into cardiac graft. 
2.7.3 Continuous telemetric monitoring 
The telemetric data were acquired, processed and recorded continuously (fig.2.7). 
The following parameters were displayed online: 
• Blood pressure waves of left ventricle of the graft 
• Blood pressure waves of the aorta 
• Epicardial ECG of the graft 
• Systolic, diastolic and mean pressure of left ventricle of the graft 
• Systolic and diastolic pressure of the aorta 
• HR derived from pressure waves of left ventricle of the graft 
• HR derived from ECG of the graft 
• Temperature measured at the transmitter housing. 
Two baboons could be monitored simultaneously if necessary. 
Ventricular 
catheter 
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Figure 2.7: Monitor of the telemetry system displaying multiple telemetric parameters 
of a recipient baboon simultaneously.  
Generally, this system was used to monitor cardiac hemodynamics and detect 
cardiac events, allowing timely initiation of therapy. Due to wireless signal 
transmission, no impairment was inflicted on the animal.  
2.7.4 Derived parameters 
Ponemah (DSI Ponemah Physiology Platform, Data Sciences International Inc, MN, 
USA) was used for data acquisition and analysis. These following parameters were 
derived from recorded data: 
LVPSP: denotes the peak values of left ventricular pressure (figure 2.8). 
LVEDP: represents the pressure in the left ventricles at the end of diastole. End of 
diastole was derived from the ventricular pressure waveform (figure 2.8). 
HR: based on the R-R intervals of the ECG. 
+dP/dtmax: defined as the maximal rate of rise of left ventricular pressure within one 
pulse (figure 2.8). 
-dP/dtmax: defined as the maximal rate of decline of left ventricular pressure within 
one pulse (figure 2.8). 
QRSA: defined as the amplitude between the lowest trough and highest peak of a 
QRS complex in ECG (figure 2.9). 
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Absolute Values of Deviation of S-T segment: deviation of S-T segment from 
baseline was measured 80ms after the endpoint of a QRS complex (figure 2.9). 
Duration of QRS complex: defined as the time span between the start and end of a 
QRS complex (figure 2.9). 
   
Figure 2.8: Measurement of hemodynamic and ECG variables.  
    
Figure 2.9: ECG of the graft. 
2.7.5 Timepoints 
Timepoints for data analysis were set daily at 6:00 in the morning, when these 
animals were not subject to manipulation or medication and artefacts caused by 
these possible factors were ruled out. 
 
Ventricular 
pressure wave 
Aortic 
pressure wave 
ECG of graft 
LVEDP
LVPSP-dP/dtmax 
P 
+dP/dtmax 
QRSA 
S-T 
Deviation
o 
Duration 
of QRS 
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2.8 Group categorization 
According to the postoperative troponin and APA serum level changes, the seven 
experiments were categorized as elevated troponin (ET) or unelevated troponin (UT) 
and as elevated (EA) or unelevated APA level (UA).  
Elevation of troponin level was defined empirically as a rise in troponin serum 
concentration of more than 3ng/ml/24h. For each experiment the time point of 
elevation was defined by the highest increase between all observed days. 
Elevation of APA was defined as an increase to over 1000 AUC. The time point 
of elevation was defined as the day on which the level of APA reached 1000 AUC. 
For technical reasons of the performed ELISA, the threshold of APA level was 
reduced to 100 AUC in baboon 3. 
2.9 Endpoints of the study 
Endpoints of the study are defined as follows: 
A. Graft failure: Indicated by no bioelectrical signals in the ECG and no mobility 
of myocardium in TTE 
B. Intolerable pain or stress of the animal: (evaluated daily, score sheet shown in 
Appendix B) 
C. Death of the baboon 
In case of condition A or B, the animal was euthanized. For euthanasia, the 
baboon was anesthetized by using 10 mg / kg ketamine hydrochloride and 0.5 mg / 
kg midazolam and an overdose of pentobarbital (80-160mg / kg Narcoren®, Merial, 
Halbergmoos, Germany) was given afterwards. 
2.10 Statistical methods  
The data were presented as Mean ± SD (standard deviation). The t-test and one-way 
analysis of variance (ANOVA) were applied for statistical analysis with p<0.05 
considered significant. The statistical analysis and other representations were 
conducted by the software Sigmaplot 11.0 (SigmaPlotTM, Systat Software Inc, USA). 
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3 Results 
3.1 Basal analysis 
In this study, the longest survival achieved among them amounted to 37 days with a 
median survival of 17 days. The endpoint events in this study consist of three 
endpoint A, three endpoint B and one endpoint C. 
Using the telemetric system, we were able to acquire, process and record the 
experimental data continuously during the course of the study. However, due to 
technical failures, transmission of radio frequency signals between the transmitter 
and receiver were disrupted occasionally, resulting in loss of telemetric data for three 
timepoints in one baboon. Additionally, determination of APA and troponin are 
unavailable at some timepoints in four baboons because of failure to obtain serum 
samples from them. Based on the measurements of the investigated telemetric 
parameters available for individual baboon recipients during the post-transplant 
period, an overall descriptive analysis of all parameters was performed and 
summarized in table 3.1. Similarly, descriptive analysis for individual baboons was 
conducted and summarized separately in table 3.2 – 3.8.  
 
Table 3.1: An overall descriptive analysis of individual parameters. 
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These parameters were plotted against postoperative days and presented in 
figure 3.1 – 3.8. Generally, the visual observation of the changes of the investigated 
parameters revealed a high heterogeneity among the recipients and there seems to 
be no uniform pattern that visually fits their changes over time. The results for these 
recipients are briefly described individually as follows. 
In baboon 1, elevation of both troponin and APA levels was recorded in the 
last postoperative week. As seen from figure. 3.1e, the levels of both troponin and 
APA stayed at a high level on POD 1 and declined sharply until POD 6 and POD 7 
respectively. Afterwards, both of their levels maintained flat until they began to rise 
on POD 17 and POD 16. In contrast, LVPSP, +dP/dtmax, -dP/dtmax, HR and QRSA 
were shown to have been declining continuously from then on, until the end. As for 
LVEDP, duration of QRS complex and deviation of S-T segment their levels 
appeared to fluctuate modestly from the day of operation onward (due to technical 
failures, telemetric data of POD 9-11 were unable to be acquired) (figure 3.1a-d).  
As for baboon 2, the level of APA began to rise on POD 11, while the level of 
troponin returned to a low level on POD 6 and stayed constant (figure 3.2e). From 
POD 14 onwards, LVPSP and +dP/dtmax increased, while QRSA appeared to 
decrease until the end. Concerning the changes of the other parameters, no clear 
trend lines were shown during the postoperative period (figure 3.2a-d).  
Elevation of both APA and troponin was recorded postoperatively in baboon 3. 
Specifically, APA level began to begin to rise on POD 7 until POD 13 (The 
measurements of APA on POD 14-17 were unavailable), while troponin level started 
to increase on POD 16 (figure 3.3e). Coincidentally, downward trend lines were 
documented for the parameters LVPSP, +dP/dtmax, -dP/dtmax, HR and QRSA from 
POD 15 onwards. LVEDP, duration of QRS complex and deviation of S-T segment 
appeared to fluctuate during the entire postoperative period (figure 3.3a-d). 
APA level of baboon 4 was observed to markedly rise from POD 9 onwards, 
while troponin level appeared unchanged during the same period (figure 3.4e). 
Apparently, LVEDP and ECG parameters maintained constant throughout the 
postoperative period (figure 3.4a, figure 3.4c, and figure 3.4d). Despite wide 
fluctuations in LVPSP, +dP/dtmax, -dP/dtmax and HR, there were no clear downward 
or upward trend lines demonstrated in the corresponding graphs (figure 3.4a-c).  
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In baboon 5, an upsurge of both APA and troponin levels was documented for 
the last few postoperative days, which started on POD 11 and POD 17 (figure 3.5e). 
LVPSP and HR appeared to decline continuously from POD15 onwards (figure 3.5a, 
figure 3.5c), while +dP/dtmax, -dP/dtmax and QRSA started to drop on POD 18. 
Regarding other parameters, no clear trends were detectable in their curve patterns 
except extremely higher LVEDP of the cardiac xenograft on POD 7, POD 8 and POD 
9 (figure 3.5a-d). 
Baboon 6 survived the longest in this group. Its APA level was suppressed at 
a considerably low level for the entire postoperative period (figure 3.6e). After the 
first week post operation, troponin level maintained low until a rise was recorded on 
the last two days. Simultaneously, there were decreases of LVPSP, +dP/dtmax, -
dP/dtmax, QRSA and HR (figure 3.6a-c).  
As for baboon 7, the measurements of APA and troponin were unavailable on 
POD 14 and POD 11 respectively. Levels of both APA and troponin maintained low 
for the last week of the postoperative period (figure 3.7e). HR, +dP/dtmax and -
dP/dtmax dropped over the last two days, while LVPSP stayed at a high level. During 
the entire postoperative period, the other parameters appeared relatively unchanged 
(figure 3.7a-d). 
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Figure 3.1(a-e): Measurement of hemodynamic and ECG parameters and serum 
level of troponin and APA of baboon 1 during the postoperative period. Table 3.2: 
Descriptive analysis of individual parameters for baboon 1. 
 
Figure 3.1c 
Table 3.2 
Figure 3.1b Figure 3.1a 
Figure 3.1d 
Figure 3.1e 
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Figure 3.2(a-e): Measurement of hemodynamic and ECG parameters and serum 
level of troponin and APA of baboon 2 during the postoperative period. Table 3.3: 
Descriptive analysis of individual parameters for baboon 2. 
Figure 3.2a Figure 3.2b 
Figure 3.2d 
Figure 3.2e 
Figure 3.2c 
Table 3.3 
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Figure 3.3(a-e): Measurement of hemodynamic and ECG parameters and serum 
level of troponin and APA of baboon 3 during the postoperative period. Table 3.4: 
Descriptive analysis of individual parameters for baboon 3. 
Figure 3.3a 
Figure 3.3d 
Figure 3.3e 
 
Figure 3.3c 
Figure 3.3b 
Table 3.4 
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Figure 3.4(a-e): Measurement of hemodynamic and ECG parameters and serum 
level of troponin and APA of baboon 4 during the postoperative period. Table 3.5: 
Descriptive analysis of individual parameters for baboon 4. 
Figure 3.4a 
Figure 3.4d 
Figure 3.4b 
Figure 3.4c 
Figure 3.4e Table 3.5 
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Figure 3.5(a-e): Measurement of hemodynamic and ECG parameters and serum 
level of troponin and APA of baboon 5 during the postoperative period. Table 3.6: 
Descriptive analysis of individual parameters for baboon 5. 
Figure 3.5a Figure 3.5b 
Figure 3.5d Figure 3.5c 
Figure 3.5e Table 3.6 
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Figure 3.6(a-e): Measurement of hemodynamic and ECG parameters and serum 
level of troponin and APA of baboon 6 during the postoperative period. Table 3.7: 
Descriptive analysis of individual parameters for baboon 6. 
Figure 3.6a Figure 3.6b 
Figure 3.6c Figure 3.6d 
  
Figure 3.6e Table 3.7 
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Figure 3.7(a-e): Measurement of hemodynamic, ECG parameters and serum level of 
troponin and APA of baboon 7 during the postoperative period. Table 3.8: Descriptive 
analysis of individual parameters for baboon 7. 
Figure 3.7a 
Figure 3.7d 
Figure 3.7e 
Figure 3.7c 
Figure 3.7b 
 Table 3.8 
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3.2 Group categorization based on profile of APA and troponin level elevation 
Based on the criterion of group categorization described in the section 2.8, four 
recipients were classified into group ET and three into group UT. Additionally, five 
were classified as EA and two as UA.  
For technical reasons of the performed ELISA, the antibody measurements of 
baboon 3 were one order of magnitude lower compared to the other recipients. 
Accordingly, the threshold was lowered to 100 AUC. 
   
ET= Group with elevated troponin serum level, UT= Group with unelevated troponin serum level. 
EA= Group with elevated APA serum level, UA= Group with unelevated APA serum level. 
Table 3.9: Profile of postoperative elevation of APA and troponin levels 
3.3 Comparative analysis of hemodynamics and ECG during the first week 
and last week post operation 
All hemodynamic and ECG parameters were compared between baboons of group 
ET (n=4) and those in group UT (n=3) for each day of both the first and last 
postoperative weeks. There was no significant difference between group ET and 
group UT during both the first and last postoperative weeks in terms of LVEDP and 
duration of QRS complex (p>0.05) (figure 3.8a, figure 3.8b, figure 3.8m, figure 3.8n). 
HR and QRSA were significantly lower in group ET compared to group UT on day 6 
(104 ± 9 vs 134 ± 11beats/min, 0.70 ± 0.30 vs 2.15 ± 1.03 mV) (p<0.05) and 7 (82 ± 
11 vs 124 ± 7 beats/min, 0.31 ± 0.09 vs 2.16 ± 1.15 mV) (p<0.05) of the last 
postoperative week (figure 3.8i, figure 3.8j, figure 3.8k and figure 3.8l). LVPSP of 
group ET didn’t differ from that of group UT during the first and last postoperative 
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week with the exception of day 5 (145 ± 21 vs 200 ± 21 mmHg) (p<0.05), 6 (84 ± 28 
vs 213 ± 8 mmHg) (p<0.01) and 7 (45 ± 33 vs 212 ± 42 mmHg) (p<0.01) of the last 
postoperative week. On these days LVPSP of group ET was significantly lower 
compared to group UT (figure 3.8c and figure 3.8d).  
Accordingly, for +dP/dtmax, no significant difference was observed between 
the two groups during the first postoperative week, but it was significantly lower in 
group ET on day 6 (1466 ± 531 vs 3125 ± 166 mmHg/s) (p<0.01) and 7 (638 ± 237 
vs 2565 ± 940 mmHg/s) (p<0.05) and higher on day 1 (3183 ± 306 vs 1801 ± 918 
mmHg/s) (p<0.05) of the last postoperative week compared to group UT (figure 3.8e 
and figure 3.8f). In contrast, there was a significant difference in -dP/dtmax between 
group ET and group UT on day 4 (2548 ± 539 vs 1515 ± 283 mmHg/s) (p<0.05) of 
the first postoperative week and day 6 (1011 ± 540 vs 2023 ± 373 mmHg/s) (p<0.05) 
and 7 (834 ± 158 vs 1600 ± 437 mmHg/s) (p<0.05) of the last postoperative week 
(figure 3.8g and figure 3.8h). No significant difference was observed in deviation of 
S-T segment between group ET and group UT during both the first and last 
postoperative weeks (p>0.05) (figure 3.8o and figure 3.8p).  
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Figure 3.8(a-p): Comparison of hemodynamic and ECG parameters between groups 
with elevated troponin (n=4) and unelevated troponin level (n=3) during the first week 
and last week post operation (* p<0.05 and **p<0.01 are considered statistically 
significant).  
* 
** 
** 
* ** * 
Figure 3.8a Figure 3.8b 
Figure 3.8c Figure 3.8d 
Figure 3.8e Figure 3.8f 
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Figure 3.8(a-p): Comparison of hemodynamic and ECG parameters between groups 
with elevated troponin (n=4) and unelevated troponin level (n=3) during the first week 
and last week post operation (* p<0.05 and ** p<0.01 are considered statistically 
significant).  
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Figure 3.8(a-p): Comparison of hemodynamic and ECG parameters between groups 
with elevated troponin (n=4) and unelevated troponin level (n=3) during the first week 
and last week post operation (* p<0.05 and **p<0.01 are considered statistically 
significant). 
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3.4 Temporal changes of hemodynamic and ECG parameters in relation to 
elevation of serum level of troponin 
Baboons of group ET were analysed based on the starting time points of elevation of 
troponin serum level presented (table 3.9). Data of hemodynamic and ECG 
parameters were compared between one day before and two days after elevation of 
troponin serum concentration (figure 3.9a-d). 
LVEDP remained unchanged during the observed period. In contrast, the level 
of LVPSP was significantly lower on the 1st (84 ± 28 vs 146 ± 21 mmHg) (p<0.05) 
and 2nd (45 ± 33 vs 146 ± 21 mmHg) (p<0.01) day after elevation of troponin 
compared to the day before that (figure 3.9a). 
Similarly, +dP/dtmax was significantly lower on the 2nd day (668 ± 329 vs 2337 
± 858 mmHg/s) (p<0.05) after elevation of troponin compared to the day before that. 
–dP/dtmax was significantly lower on the 1st (1511 ± 540 vs 2843 ± 418 mmHg/s) 
(p<0.05) and 2nd (834 ± 158 vs 2843 ± 418 mmHg/s) (p<0.05) day after elevation of 
troponin than on the day before (figure 3.9b). 
As for QRSA, a downward trend was observed during these days. 
Significantly lower readings were obtained on the 1st (0.70 ± 0.30 vs 2.19 ± 1.09 
mV) (p<0.05) and 2nd (0.31 ± 0.09 vs 2.19 ± 1.09 mV) (P<0.01) day after elevation of 
troponin compared to the day before (figure 3.9d). Absolute values of deviation of S-
T segment were also compared, but no significant difference was observed between 
those days (p>0.05). 
A gradual decline of heart rates of xenografts was recorded after elevation of 
troponin level and the difference was significant between its values obtained on the 
day before and the 1st (104 ± 7 vs 119 ± 9 beats/min) (p<0.05) and 2nd (82 ± 9 vs 119 
± 9 beats/min) (p<0.01) day after elevation of troponin, whereas changes of duration 
of QRS complex were not significant during the same period (figure 3.9c).  
Analysis of APA serum level showed no significant difference in APA serum 
level between the day before and the two days after elevation of troponin in the 3 
baboons from which serum samples were available (p>0.05). 
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Figure 3.9(a-e): Comparison of hemodynamic and ECG parameters before and after 
elevation of the serum level of troponin (*p<0.05, **p<0.01 mean significant). 
Figure 3.9a Figure 3.9b 
Figure 3.9c Figure 3.9d 
Figure 3.9e 
* 
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○  ** 
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** 
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3.5 Temporal changes of hemodynamic and ECG parameters in relation to 
elevation of serum level of anti-pig antibody (APA) 
Marked increases of serum level of anti-pig antibody were observed in baboon 1, 
baboon 2, baboon 3, baboon 4 and baboon 5 during the postoperative period (table 
3.9). Changes of hemodynamic and ECG variables after elevation of APA were 
analysed in this group.  
Before and after elevation of APA, LVEDP and LVPSP of cardiac xenografts 
varied slightly and no significant difference was observed in these hemodynamic 
parameters (p>0.05) (figure 3.10a). Though decreased values of ±dP/dtmax were 
recorded for two consecutive days after APA started to rise, they were not 
significantly lower compared to the day before the rise of APA level (p>0.05) (figure 
3.10b). Similarly, heart rates and duration of QRS complex appeared to fluctuate 
modestly throughout the period without any significant changes (p>0.05) (figure 
3.10c). 
Notably, during this period, troponin level rose moderately over time and a 
gradual drop of QRSA was observed. However, no significant changes were 
detected in both of them (p>0.05) (figure 3.10d and figure 3.10e).  
Additionally, absolute values of deviation of S-T segment was compared 
between the day before and two days after elevation of APA level, but no significant 
difference was observed (p>0.05) (figure 3.10d). 
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Figure 3.10(a-e): Comparison of hemodynamic and ECG parameters before and 
after elevation of the serum level of APA.  
Figure 3.10a 
Figure 3.10d Figure 3.10c 
Figure 3.10b 
Figure 3.10e 
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4 Discussion 
In recent years, the heterotopic thoracic cardiac transplantation technique has been 
established as a preclinical pig-to-baboon cardiac xenotransplant model. As the 
circulation of the recipient is not fully dependent on xenograft function, the systemic 
circulation of the recipient can still be maintained by the native heart in case of graft 
failure. In this xenotransplant setting, the implemented technique enables recipients 
to survive the critical early posttransplant period associated with higher risk of acute 
xenograft rejection. Thus, this model, which is thought to combine the advantage of a 
working heart model and the safety of heterotopic cardiac transplantation, could 
open a new path for addressing relevant immunological issues.  
As mentioned above, xenograft function only contributes partly to the recipient's 
circulation, which still can be maintained by its native heart in the event of graft 
failure. Therefore, it could not be accurately and timely reflected by the recipient's 
hemodynamic status, necessitating continuous monitoring to identify cessation of 
graft function. Moreover, due to the unconventional placement of xenograft in the 
thoracic cavity, palpation of the graft is not possible. Thus, to overcome these 
problems, we proposed telemetry as means to achieve continuous monitoring of 
xenograft function in this study. 
4.1 Telemetric detection of rejection episodes 
In this study, due to successful avoidance of hyperacute rejection by αGalT-knockout 
genetical modification of pig donors, cardiac xenograft function was well preserved in 
the seven baboons during the first week post transplantation, as indicated by 
maintenance of normal graft hemodynamics during the period. However, from the 
second postoperative week onward, acute humoral rejection remains an 
insurmountable barrier to these recipients’ long survival in this study and graft 
function ceased mostly in the second or third week post transplantation. In these 
recipients xenoreactive antibody response or myocardial damage occurred as 
evidenced by elevation of anti-pig antibody or troponin serum level, resulting in 
impaired graft function as reflected by deterioration of a series of hemodynamic and 
ECG variables including LVPSP, ±dP/dtmax, QRSA and HR. There is no doubt that 
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multiple parameter telemetric monitoring enables more comprehensive and detailed 
evaluation of cardiac graft function as compared to traditional manual palpation or 
auscultation aimed at heart rate count, allowing prompt intervention and reversal of 
possible rejection at an early stage. However, not all telemetric parameters have 
predictive values in detecting deterioration of cardiac graft function in case of acute 
cardiac rejection in the setting of telemetry monitoring. Thus, to identify the reliable 
hemodynamic and ECG indicators of acute cardiac rejection, which can be readily 
analysed and used as evidences to justify the following therapeutical intervention in 
combination with other relevant parameters during the critical early postoperative 
period, is of particular significance. To this end, the major hemodynamic and ECG 
variables mentioned above were retrospectively analysed and compared between 
recipients with and without postoperative elevation of troponin serum level, and 
within the group of recipients with elevated troponin level. 
It was found LVPSP, ±dP/dtmax, HR and QRSA were significantly lower in the 
group with elevation of troponin level compared to the other group on the last two 
days prior to cessation of graft function, indicating that LVPSP, ±dP/dtmax, HR and 
QRSA are closely relevant to troponin serum level and reflect the alteration of graft 
function resulting from myocardial damage accurately. However, there was no 
evidence that LVEDP was correlated with troponin level in this study, as opposed to 
the finding of a previous similar study which suggested LVEDP was a parameter as 
valuable as LVPSP for evaluation of cardiac graft function during the cardiac 
posttransplant period [79]. Furthermore, LVEDP was maintained relatively constant 
throughout the entire postoperative period in recipients either with or without 
elevated troponin level except extremely higher LVEDP of baboon 5’s cardiac graft 
was observed on POD 7, POD 8 and POD 9, for which we still have no reasonable 
explanation so far. This finding could be explained by the fact that LVEDP is 
determined by left ventricular compliance which is a continuously changing variable 
during the first few hours or days after acute myocardial infarction and due to an 
interaction of normal and infarcted cardiac muscle, LV compliance is increased 
rather than decreased in this short period. Thus, LVEDP may be lower for any given 
end diastolic volume immediately after acute myocardial infarction [80]. However, as 
a result of fibrocellular infiltration, ventricular compliance is diminished during the 
healing phase of acute myocardial infarction and LVEDP is elevated accordingly in 
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the meantime. In the present study, considerable myocardial damage was found to 
occur mostly two or three days prior to graft failure, as evidenced by marked 
elevation of troponin serum level. Thus, it is not difficult to understand why LVEDP 
remained unchanged shortly after troponin serum levels were elevated. 
Nevertheless, it is assumed that LVEDP will be elevated dramatically as a result of 
further myocardial damage in the long term. Unfortunately, due to immediate failure 
of xenografts after acute rejection, we failed to conduct further investigation to 
validate this viewpoint. 
To assess the graft’s overall left ventricular function, evaluation of contraction 
and relaxation of the left ventricle (LV) should be involved. With respect to the 
contractile phase, many investigators have used cardiac contractility as a factor to 
gauge LV systolic function [81–84]. Myocardial contractility is the intrinsic ability of 
myocytes to exert force at a certain length and it increases upon sympathetic 
stimulation. Normally, cardiac contractility is expressed as the maximum changing 
pressure divided by the change of time and it denotes the maximal rate of elevation 
of intracardiac pressure during isovolumic contraction expressed as +dP/dtmax [85–
89]. Ventricular relaxation is utilized to evaluate left ventricular diastolic function and 
it is often expressed either as the maximum (negative) change in pressure divided by 
the change of time [90–94], which denotes the maximal rate of decline of left 
ventricular pressure during isovolumic relaxation expressed as -dP/dtmax. As a 
result of contraction and relaxation activity, intracardiac pressure of different phases 
reflects cardiac function directly. As for the left ventricular function, LVPSP and 
LVEDP are two of the most commonly used parameters for its evaluation, which are 
conventionally utilized as indicators of left ventricular systolic and diastolic function 
respectively and constitute an essential part of hemodynamic analysis in either 
clinical or experimental setting. Therefore, in this study, to accomplish a systemic 
evaluation of xenograft function, we proposed the use of the aforementioned 
hemodynamic parameters. Notably, based on a comparative analysis (Section 3.3), 
LVPSP seemed to be the most sensitive parameter for evaluation of overall cardiac 
xenograft function among these four parameters thanks to its more significant and 
prompt change compared to other parameters at the time of changes of graft 
hemodynamics. 
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During episodes of rejection, the electrophysiological state of the transplanted 
heart is altered. These changes may be monitored by use of the electrocardiogram.  
The surface and intramyocardial electrocardiogram have been used as non-invasive 
technique for the diagnosis of cardiac allograft rejection for many years [95–98]. 
Alteration in conduction, amplitude of QRS complex and rhythm was thought to be 
associated with episodes of rejection. In one study, intramyocardial ECG analysis 
indicated QRS amplitude was a reliable indicator of acute cardiac rejection with a 
sensitivity of 95% and specificity of 78% [99]. Müller, et al validated the role of QRS 
amplitude in diagnosing rejection in heart transplant children, which was monitored 
continuously using a telemetric technique and suggested diagnosis of rejection could 
be established when QRS amplitude fell more than 8% below average baseline 
levels for three consecutive days [100]. Thus, determination of amplitude of QRS is 
an accurate method for the early detection of cardiac rejection. As expected in this 
study, a continuous QRS amplitude loss was observed as troponin serum level 
began to rise dramatically indicating a correlation between QRS amplitude and 
rejection-related myocardial damage. 
  QRS duration is a reliable predictor of underlying myocardial injury even in the 
normally functioning left ventricle and its prolongation, which results from left bundle 
branch block, is well associated with transmural myocardial damage [101,102]. As 
for its application in predicting acute cardiac rejection, little is known to date except a 
couple of surface ECG analysis indicating QRS duration didn’t show any 
characteristic change during rejection episodes in orthotopic heart transplant patients 
[103,104]. In the present study, QRS duration of cardiac xenograft did not show any 
significant change after elevation of troponin level despite a continuous slight 
increase observed during the following two days. However, due to limited number of 
subjects and possible statistical bias, the results should be interpreted with caution 
before further study involving large number of subjects is available to validate this 
finding. 
In this study, S-T segment deviation, as a conventional marker of myocardial 
ischemia and infarction in ECG analysis, was also documented and analysed, which 
occurs in the form of either elevation or depression. In order to enable comparison 
between negative and positive voltages representative of depression and elevation 
of S-T segment respectively, absolute values of the measurements were adopted for 
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computing and statistical analysis. Deviation of S-T segment was commonly 
observed in ECG of all the recipients postoperatively either in the form of elevation or 
depression. However, this ECG parameter appeared to show no significant changes 
associated with alteration of troponin and APA level. Though elevation and 
depression of S-T segment are associated with both acute ischemia and infarction, it 
may also have links to non-ischemic events, such as left bundle branch block, left 
ventricular hypertrophy [105,106], which are likely to be involved in the postoperative 
course, complicating identification of the exact cause of S-T segment deviation 
observed. In this study, though we did not observe any significant change in this 
ECG variable associated with elevation of troponin serum level, it might be assertive 
to exclude this variable as a possible predictor of acute rejection just based on the 
finding of this study. Furthermore, investigation of S-T segment deviation in cardiac 
transplant setting has been poorly described before. Consequently, with regard to 
the predictive value of this variable for acute rejection further studies are warranted. 
In addition, there is still no standard technique for placement of the ECG leads into 
the epicardium in the setting of intramyocardial ECG and variation in epicardial 
location of the leads may affect determination of ST-segment positive and negative 
vectors, leading to possible artefacts in the signal data acquisition. Therefore, 
standard placement procedures also need to be established in order to achieve 
accurate acquisition of myocardial bioelectric signals with fewer artefacts.  
Other electrocardiographic parameters such as R wave amplitude, the QT and 
QTc interval have been investigated as predictors of acute cardiac rejection [104, 
107,108]. Based on our experience in monitoring and analysing these variables, it is 
preferable to apply amplitude analysis rather than interval analysis as means for 
early detection of acute cardiac rejection in the setting of telemetric monitoring as 
analysis of intervals is much more difficult to perform than that of amplitudes in some 
cases where atypical electrocardiography patterns make it hard to characterize the 
waves and define the interval parameters accurately. Furthermore, it was reported 
that amplitude analysis has a sensitivity of 100% and a specificity of 86% for the 
diagnosis of rejection while interval analysis is not predictive of rejection even when 
conduction is prolonged with intervention in a similar intramyocardial ECG analysis 
[108]. In general, alteration of these electrocardiographic variables occurs early in 
the time course of acute xenograft rejection and analysis of their measurements may 
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lead to earlier detection of episodes of rejection. This would allow treatment to be 
instituted more expeditiously and minimize damage to the graft. 
4.2 The role of troponin in detecting acute rejection-related myocardial 
damage 
Cardiac troponin I (cTnI) serves as a useful and sensitive marker of myocardial 
damage because of its cardiospecificity [109]. Based on its role in diagnosing 
myocardial damage, cTnl was also proposed as a marker of acute rejection following 
cardiac transplantation by some studies. For instance, Dengler, et al [110] reported 
increasing troponin concentration paralleled with the severity of graft rejection. 
Despite some researchers arguing that troponin T and troponin I may not be reliable 
markers of cardiac transplant rejection [111-113], some studies demonstrated that 
cTnI is still a specific marker of acute cardiac rejection despite its limitations of 
sensitivity [114]. Undoubtedly, endomyocardial biopsy (EMB) is still deemed the “gold 
standard” for diagnosing cellular rejection after cardiac transplantation due to its high 
sensitivity and effectiveness. However, biopsies are not a practical screening tool 
and cannot be done repeatedly to detect rejection before myocardial damage [115]. 
Moreover, due to complexity of anatomical location of the graft relative to the native 
heart, EMB is actually impractical technically for heterotopic thoracic models involved 
in this study. Additionally, the potential lethal injury and infection EMB procedures 
might cause to recipients are also concerns investigators should take into 
consideration before performing it. Thus, we still propose determination of serum 
cardiac troponin I level as an effective method to detect possible acute cardiac 
rejection. 
 In this study, we demonstrated that in all baboons in which we suspected an 
episode of acute rejection based on elevation of troponin serum level, the functional 
telemetric parameters underwent some characteristic changes. A significant 
decrease could be observed in LVPSP, ±dP/dtmax, HR and QRSA after obvious 
elevation of troponin serum level in all of these baboons, suggesting close 
correlation between these telemetric variables and troponin level. Normally, elevation 
of troponin level occurred two or three days prior to cessation of graft function in 
these recipients. A comparative analysis (Section 3.3) also indicated significant 
difference in these telemetric parameters between recipients with and without 
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elevation of troponin level during the last two days post operation, further validating 
the correlation of troponin level with these parameters from another perspective. 
Additionally, an extraordinarily large amount of troponin was released right after 
operation in all the recipients, leading to extremely high level of troponin 
concentration in the peripheral circulation, which was associated with intraoperative 
surgical procedure-related myocardial damage of both the native heart and graft 
rather than any episode of rejection. The extraordinarily high postoperative troponin 
level was not thought to be associated with any deterioration of the investigated 
telemetric variables. Thereafter, the serum concentration of troponin decreased 
gradually and normally took about one week to reach a low level, which was 
maintained until occurrence of myocardial damage associated with acute rejection.  
4.3 The role of Anti-pig antibody in detecting acute xenogeneic rejection 
Despite the use of intensive immunosuppressive regimen and GalT-KO transgenic 
organ-source pigs, acute humoral xenograft rejection remains a major barrier to long 
term survival of cardiac xenografts in pig-to-primate xenotransplant model, which is 
characterized by thrombotic microangiopathy and associated with the presence of 
preformed and/or elicited anti-pig antibodies (anti-Gal and anti-non-Gal). In the 
present study, although anti-pig antibody could be diminished by immunoadsorption 
over the period of a few days after transplantation, anti-pig antibody reemerged as a 
result of a T-cell dependent antibody response, inevitably leading to AXHR. An anti-
pig antibody hemolytic assay was employed to monitor the peripheral anti-pig 
antibody response of recipient baboons on a daily basis post transplantation, which 
represents a cytolytic activity assay. In this study, APA serum concentration was 
suppressed at a low level during the first postoperative week due to perioperative 
intensive immunosuppression. Afterwards, considerable elevation of APA was 
observed in the second week in five recipients. Notably, only three of them were 
shown to have dramatic elevation of troponin levels subsequently. Not all the 
elevation of anti-pig antibody levels inevitably led to the elevation of troponin levels in 
these recipients during the postoperative period. On the other hand, the elevation of 
troponin level is not always associated with the elevation of anti-pig antibody level, 
as in one of four recipients with elevation of troponin level, no marked increase of 
anti-pig antibody level was recorded at all. Furthermore, no significant change of any 
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hemodynamic parameters or ECG variables was observed following the elevation of 
anti-pig antibody level. All these findings might suggest that anti-pig antibody serum 
level maybe is not a perfect indicator of acute humoral xenograft rejection, which is 
invariably followed by various degrees of myocardial injury and impairment of 
xenograft function. This is in agreement with the findings of Richards, et al [116], 
which indicated no individual assay for serum anti-pig antibody measurement was 
consistently predictive for AHXR and suggested multiple assays be employed in 
detection of elicited anti-pig antibody response associated with AHXR.  
That is why we proposed to perform hemagglutination assay, anti-Gal assay 
and binding assays of IgG and IgM simultaneously as means to detect episodes of 
acute cardiac rejection in another study.  
Furthermore, Richards, et al argued that the mere presence of anti-pig 
antibodies in the periphery does not necessarily imply that they are destructive to the 
graft unless it is certain that these antibodies are definitely bound to the endothelial 
cells of the graft and the bound antibodies are involved in damaging the graft. 
Previous studies indicated that anti-Gal antibodies may exert a non-destructive effect 
on the xenografts by either inducing accommodation of the target cells or inhibiting 
the binding of cytotoxic antibodies to the grafts [117, 118]. Moreover, there were also 
several examples of relevant antibody levels in the circulation without an apparent 
decline in graft function. Additionally, it is also postulated that in case of APA-
mediated acute rejection, there is a “time window” between occurrence of rejection 
episodes and onset of myocardial damage, ranging from a few hours to a few days 
and featuring a series of pathological events including cellular infiltration, interstitial 
edema and haemorrhage before myocytes are damaged and cardiac graft function is 
impaired, leading to a drop in QRSA and compromised systolic and diastolic function 
eventually. This point also needs to be considered when explaining dyssynchronous 
changes in APA and troponin serum level and other investigated parameters. Thus, 
further work is needed to ascertain not only the effects of individual components of 
anti-pig antibodies on the xenografts but also their specific roles in AHXR and their 
relationship with other predictors. 
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4.4 Advantages and disadvantages of telemetric monitoring technique in 
experimental cardiac xenotransplantation 
In this study, a telemetric technique was applied and assessed with a focus on 
analysis of the alteration of a variety of telemetric variables following pig-to-non-
human primate cardiac xenotransplantation in an attempt to explore the possibility of 
using this technique for detection of possible acute xenograft rejection in 
combination with other surveillance techniques. To sum up, in the context of cardiac 
xenotransplant, the advantages of the system are as follows: Telemetry allows 
monitoring of the graft without restraint stress to the animal. Consequently, stress-
induced artefact is significantly reduced. It permits long-term, long-range and 
wireless monitoring of conscious, freely moving laboratory animals. Furthermore, it 
enables continuous and simultaneous monitoring of multiple parameters in more 
than one animal. Telemetric measurements are free from the effects of anesthesia 
and experimental data can be recorded and stored in a real-time manner by the 
system, and retrospective analysis of the data is also made possible. Data obtained 
by telemetry contains no cable or commutator artefacts commonly seen in the wiring 
monitoring systems. Despite these aforementioned benefits brought by this novel 
technique, a couple of disadvantages still remain, including the complex surgical 
procedures for implantation of the transmitter may result in prolonged intraoperative 
cardiac arrest, which can be associated with worse graft function postoperatively. 
Additionally, the possible infection posed by subcutaneous implantation of devices 
and ECG electrodes may lead to an increased mortality rate of recipients maintained 
on long-term immunosuppressive regimen following transplantation. Data loss or 
distortion may be caused by technical failures of the transmitter unit such as catheter 
and electrode displacement, electronic component failures and battery problem, 
which are unsolvable due to their inaccessible positions. Radio frequency 
transmission of signals between the transmitter and receiver tends to be disrupted by 
radio frequency interference and electromagnetic interference by other laboratory 
instruments in the surroundings. Furthermore, the complexity of the initial equipment 
installation added to the difficulty and challenge of implementation of this technique. 
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4.5 Limitations and outlook 
The heterotopic thoracic xenotransplant model applied in this study is perceived to 
be a complex preclinical experimental model involving complicated surgical 
techniques, sophisticated medical instruments, intensive surveillance, individualized 
diagnostic and therapeutic scheme, and concerted efforts by research staff. 
Moreover, there may be many either known or unknown, controllable or 
uncontrollable factors involved in any part of the experimental process, complicating 
the interpretation of the experimental data. Even though these baboon experiments 
were subjected to a completely identical experimental condition, changes of those 
parameters in them might be totally different too. For this consideration, we observed 
and documented those parameters’ changes in individual baboons continuously, 
which gave us the first hand information in the future retrospective analysis. From 
this perspective, findings from an individual-based study may be more persuasive 
than those from any small group study. That is why we investigated these baboons 
individually and described their changes on a daily basis. 
      This study demonstrated the usefulness of a telemetry system in assessing 
xenograft function in a pig-to-non-human primate cardiac xenotransplant model, and 
indicated that LVPSP, HR, ±dP/dtmax and QRSA might be useful telemetric 
parameters for accurate prediction of acute rejection involved in cardiac 
xenotransplantation and LVPSP and QRSA may be the most sensitive predictors 
among them, due to their effectiveness in assessing graft function and closer 
correlationship with myocardial damage marker troponin. Despite the proper design 
and implementation of this study, it still has a couple of limitations. The first one is the 
limited number of recipient animals due to high financial costs and technical 
complexity of the pig-to-non-human primate cardiac xenotransplant model, which 
might lead to increased statistical biases and even erroneous conclusions on some 
occasions. Thus, further studies involving a larger number of recipients are needed 
to validate the findings obtained from the present study. Secondly, due to huge 
amount of data acquired by the telemetric system during the experiment, it is difficult 
to make detailed and complete description of all data and only data collected at 6 
o’clock of each postoperative day was selected for analysis instead. Therefore, we 
inevitably missed changes of those parameters occurring at other timepoints, which 
might make a difference in overall data analysis and were very likely to obtain biased 
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findings on some occasions. Thirdly, though troponin serum level is deemed a 
reliable indicator of rejection episodes in the setting of cardiac transplant, histological 
and immunohistochemical findings remain an irreplaceable evidence for making a 
accurate diagnosis of a rejection episode. As mentioned above, due to the 
complexity of anatomical location of the graft relative to the native heart, EMB is 
impractical technically for these heterotopic thoracic models.   
ISHLT proposed that clinical trials on human could be initiated only after 
routine survivals of a minimum of three months have been achieved for pig hearts 
which are transplanted into non-human primates in a life-supporting manner or a 
minimum of 6 month survival is achievable for these cardiac xenografts transplanted 
in a non-life-supporting manner [73].  
However, survivals for cardiac xenotransplants achieved so far that vary from a 
maximum of 57 days in life-supporting model [119] to 236 days in non-life-supporting 
model [120] is still far from this goal. We believe that the application of this telemetric 
technique will definitely contribute to acceleration of the progress towards clinical 
application of this heterotopic thoracic technique. 
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5 Summary 
Xenotransplantation is thought to have the potential to solve the critical shortage of 
donor’s hearts with the development of genetically modified organ-source pigs and 
improvement of immunosuppressive strategies. As an appropriate preclinical animal 
model, the pig-to-baboon cardiac xenotransplantation model has been widely 
adopted. Traditionally, the evaluation of cardiac xenograft function in a pig-to-baboon 
model has been accomplished by means of palpation, ultrasound and biopsy. 
However, those methods pose increased risk of complications such as bleeding, 
infection, and apnea, leading to increased morbidity and mortality. Telemetric 
monitoring systems have been widely applied in the life science research involving a 
wide variety of animal models. These systems enable non-invasive, reliable and 
continuous measurements of cardiac xenograft function and provide information 
valuable for the improved understanding of transplantation pathophysiology. 
Importantly, these systems do not only avoid repeated anesthesia of the animals but 
also allow measurements independent from the effects of anesthetics.  
In preclinical pig-to-baboon xenotransplantations, telemetry systems have only been 
used in the heterotopic abdominal experiments. The aim of this study was the 
evaluation of a telemetry system for the monitoring of cardiac xenograft function after 
heterotopic thoracic cardiac xenotransplantation. 
Seven baboons underwent heterotopic thoracic cardiac xenotransplantation, for 
which double or triple transgenic pigs were used as donors. Hemodynamic 
parameters such as left ventricular peak systolic pressure (LVPSP), left ventricular 
end diastolic pressure (LVEDP), heart rate (HR), maximal rate of rise or decline of 
left ventricular pressure (±dP/dtmax), deviation of S-T segment, and the duration and 
amplitude of QRS complex in electrocardiogram (QRSA) were continuously 
monitored, using a telemetry system (DSI, St. Paul, MN, USA). Postoperatively, the 
serum levels of anti-pig antibodies (APA) were analyzed using a hemolytic assay 
with pig erythrocytes and the serum level of troponin was determined by the clinical 
laboratory on a daily basis. Based on the changes of troponin levels and APA levels, 
the baboons were grouped into elevated and unelevated. All parameters were 
compared between groups and between days.  
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During the last two days of their survival, LVPSP, HR, +dP/dtmax, -dP/dtmax and 
QRSA were significantly lower in the baboons with elevated troponin compared to 
the group with unelevated troponin. Regarding specifically the group of baboons with 
elevation of troponin, the following observation was made: LVPSP, HR, -dP/dtmax, 
and QRSA decreased significantly on the day elevation of troponin was observed 
and the next day. In addition, The decrease of the parameter +dP/dtmax was 
significant one day after troponin increased. In contrast, the analysis of the group of 
baboons with elevated anti-pig antibodies revealed no significant changes in 
hemodynamic or electrocardiographic parameters before and after the rise of 
antibodies.  
In conclusion, this study demonstrates the ability of the telemetry system to assess 
changes in xenograft function in the heterotopic thoracic pig-to-baboon cardiac 
xenotransplant model. In particular, the parameters LVPSP, HR, ±dP/dtmax and 
QRSA are perceived to be reliable indicators of myocardial damage associated with 
graft rejection at an early stage following cardiac xenotransplantation. The use of the 
telemetry system might help to guide immunosuppressive therapy and further 
improve graft survival in future experiments. 
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6 Zusammenfassung 
Die Xenotransplantation stellt eine vielversprechende Möglichkeit dar, durch die 
Entwicklung genetisch modifizierter Schweine und einer Verbesserung 
immunsuppressiver Strategien, den zunehmenden Bedarf an Spenderorganen in der 
Transplantationsmedizin zu decken und das Problem der Knappheit menschlicher 
Spenderorgane zu lösen. Als einziges angemessenes präklinisches Tiermodell wird 
die Transplantation transgener Schweineherzen in Primaten angesehen. 
Ursprünglich wurde in diesen Versuchen die Funktion des Transplantats durch 
Palpation, Ultraschall und Biopsien überprüft. Diese Methoden bergen jedoch ein 
erhöhtes Risiko an Komplikationen, wie Blutungen, Infektionen oder Aspiration 
infolge der notwendigen Narkose, welche wiederum eine erhöhte Morbidität 
beziehungsweise Mortalität zur Folge haben können. Telemetrische Messsysteme 
sind in der Biowissenschaft weit verbreitet und werden dabei in verschiedensten 
Tiermodellen verwendet. Diese Systeme ermöglichen verlässliche und 
kontinuierliche Messungen der kardialen Funktion und liefern darüber hinaus 
wertvolle Informationen, um pathophysiologische Vorgänge verstehen zu können. 
Die Telemetrie bietet die Möglichkeit wiederholte Narkosen zu vermeiden und erlaubt 
dadurch Messungen unabhängig von etwaigen Effekten verwendeter 
Betäubungsmittel. 
Bisher wurden bei der xenogenen Herztransplantation Telemetriesysteme 
ausschließlich in heterotop abdominellen Experimenten verwendet. Ziel dieser Arbeit 
war die Evaluierung eines solchen Systems für die Überwachung der 
Transplantatfunktion nach heterotop thorakaler xenogener Herztransplantation. 
In der vorliegenden Arbeit erfolgte bei sieben Pavianen eine heterotop thorakale 
xenogene Herztransplantation mit doppel- beziehungsweise tripeltransgenen 
Schweineherzen. Durch die Verwendung eines telemetrischen Systems (DSI, St. 
Paul, MN, USA) konnten hämodynamische Parameter wie maximaler 
linksventrikulärer systolischer Druck (LVPSP), linksventrikulärer enddiastolischer 
Druck (LVEDP), Herzfrequenz (HR), maximaler Druckanstieg/Druckabfall pro 
Zeiteinheit im linken Ventrikel (±dP/dtmax) und Amplitude des QRS-Komplexes 
(QRSA) kontinuierlich überwacht werden. Postoperativ wurde die 
Serumkonzentration sogenannter anti-pig-Antikörper (APA) mittels hämolytischem 
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Schweineerythrozyten Assay bestimmt. Außerdem wurde täglich die Troponin 
Serumkonzentration als laborchemischer Marker für eine  Myokardischämie 
gemessen. Basierend auf den Veränderungen der Troponin- beziehungsweise APA-
Konzentration im Laufe eines Versuches, wurden diese in zwei verschiedene 
Gruppen (mit Anstieg / ohne Anstieg) eingeteilt. Alle Parameter wurden jeweils 
zwischen den Gruppen und innerhalb einer Gruppe an verschiedenen Tagen 
miteinander verglichen. 
Die Parameter LVPSP, HR, +dP/dtmax, -dP/dtmax and QRSA waren an den letzten 
beiden Lebenstagen der Paviane mit erhöhtem Troponin signifikant niedriger. 
Innerhalb der Gruppe der Paviane mit erhöhtem Troponin-Serum-Spiegel zeigte 
sich, dass sowohl LVPSP, HR, -dP/dtmax als auch QRSA am selben Tag und am 
nächsten Tag nach Troponinanstieg signifikant abfielen. Der Abfall des Parameters 
+dp/dtmax war erst einen Tag nach Troponinanstieg signifikant abgefallen. Innerhalb 
der Gruppe mit Anstieg der APA Konzentration konnten keine signifikanten 
Unterschiede bezüglich der hämodynamischen und elektrokardiographischen 
Parameter vor und nach dem Zeitpunkt des Antikörper Anstiegs gemessen werden. 
Zusammenfassend geht aus dieser Dissertationsarbeit hervor, dass sich  die 
Telemetrie als geeignetes System erweist, um Veränderungen der 
Transplantatfunktion im beschriebenen heterotop thorakalen xenogenen 
Herztransplantationsmodell festzustellen. Insbesondere die Parameter des LVPSP, 
der Herzfrequenz, des ±dp/dtmax und der Amplitude des QRS-Komplexes 
ermöglichen es Myokardschäden, die mit einer Abstoßungsreaktion des 
Transplantats assoziiert sind, frühzeitig zu erkennen. Möglicherweise kann das 
telemetrische Monitoring in zukünftigen Versuchen beitragen die immunsuppressive 
Therapie zu steuern und so das Transplantatüberleben weiter verbessern. 
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8 Appendix 
Appendix A:  Protocol of Anti-Pig Antibody Assay 
1. Human serum and baboon serum are heated at temperature of 56 ºC for 30 
min and then centrifuged for 5 min at full speed to get rid of small residual particles. 
2. 1×CFD-buffer (Complement fixation test diluent) is prepared by adding 50 ml 
CFD to 200 ml distilled water. This 1×CFD-buffer is used for all following steps. 
3. 3 ml pig blood is diluted in 30 ml CFD buffer. 
4. The pig blood suspension is then centrifuged at 750 g for 6 min. Supernatant 
is discarded and the centrifuge tube is filled with 30 ml CFD buffer again. This 
washing step is performed 4 times. It should be noted that it is important to wash the 
pig blood cells as thoroughly as possible in order to get rid of endogenous 
complement factor proteins from the blood. After the last round of washing the 
supernatant is discarded and the pellet is then centrifuged at the maximal speed in 
the ultracentrifuge for 5 min. 
5. 100 ul of the pellet are then transferred to a tube with 9.9 ml CFD buffer. This 
cell suspension is called PRBC (Purified Red Blood Cell). 
6. 400 ul baboon serum plus 600 CFD-buffer and 400 ul human serum plus 600 
ul CFD-buffer are mixed in 1.5 ml centrifuge tubes. 100 ul baboon serum-dilution is 
transferred to cells of A1 and B1 of the 96 well plate with cone-shaped bottom (figure 
11), respectively. If more than one baboon serum is to be assayed 100 ul of the 
second baboon serum sample is added in C1 and D1 each and 100 ul of the third 
serum sample is added in E1 and F1 each and so on for more serum samples. 
Normally, G1 and H1 are reserved for human serum with 100 ul of it added in each 
of them. 
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Figure 11: Diagram of a 96 well plate. 
7. 50 ul CFD-buffer is added in the wells from Column 2 to Column 10 as well as 
in B11 and B12. 
8. 50 ul of the diluted serum in the wells from A1 to H1 are transferred to the 
wells from A2 to H2 with a multi-channel pipette. The fluid is mixed thoroughly by 
pipetting 3 times and then 50 ul of it is transferred to the next row ( A3-H3 ) and 
mixed thoroughly as aforementioned, followed by further serum serial dilution in the 
same way in wells from Column A4-H4 to Column A12-H12. Lastly, 50 ul of Column 
A12-H12 is discarded. 
9. PRBCs are added in B11 and B12 as negative controls while A11 and A12 
(positive controls) are left empty. 
10. 50 ul PRBCs are then pipetted in the wells from Column 1 to Column 10. This 
is done by adding 50 ul PRBCs to each of the wells from A10 to H10 and then to 
each of the wells from A9 to H10 and so on, so as not to disrupt the serial serum 
dilution on the plate. This can be done with the same tips. 
All wells which are not used for assay in the plate are left empty in steps 8 and 10. 
11.  The plate is covered with a lid and incubated at the temperature of 37 ºC, 
being shaken gently for 1 hour. 
12.  After the incubation 100 ul CFD buffer is added to all serum samples on the 
plate. The fluid in each well is mixed well by repeated pipetting. Care is taken not to 
use the same tips for serum dilution and negative controls and start from A10-H10 to 
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A1-H1 so as not to change the dilution of sera on the plate. Then, the plate is 
centrifuged at 20 ºC at 500 g for 5 min. 
13.  After centrifugation pellets are checked and if no pellets are observed, 
centrifugation is repeated. As soon as pellets are detected the supernatant is 
discarded by flinging out forcibly and care is taken not to shake the plate. 
14.  200 ul CFD buffer is added to each of the wells used for the assay and mixed 
well. This step starts with the negative controls and then is performed from the 
highest dilution of serum (A10-H10) to A1-H1. It should be noted that the fresh tips 
are used for the negative controls. 
15. The plate is then centrifuged at 500 g for 10 min at 20 ºC. Afterwards the 
pellets are checked before the supernatant is discarded in the same way as that in 
step 13. 
16. To prepare Baby-rabbit-complement preparation, a pack of Baby-rabbit-
complement is dissolved by adding 1 ml distilled water as well as 9 ml CFD-buffer. 
17. 150 ul of Baby-rabbit-complement preparation is added to each well with the 
sample except A11 and A12. 
18. 100 ul distilled water and 50 ul PRBCs are added in A11 and A12 (positive 
controls). 
19. The plate is then covered with a lid and incubated at 37 ºC, being shaken for 1 
hour. 
20. Multichannel-Photometer is switched on and warmed up for at least ½ hour 
before use. 
21. The plate is taken out of the incubator and then centrifuged at 500 g for 10 
min at 20 ºC. 
22.  After centrifugation 100 ul supernatant is taken out from all the wells and 
transferred to the corresponding wells of another new plate with flat bottom for 
measurement. 
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23.  Lastly, the samples are assayed for their optical absorption values at the 
wave length of 420 nm using Multichannel-Photometer. 
  
74 
Appendix B: Score Sheet 
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